Outcomes of the Victo™ adjustable artificial urinary sphincter in the treatment of male incontinence

Abstract

ObjectivesTo report the clinical outcomes of the Victo™ (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery.Patients and MethodsThis study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively evaluated at baseline, and at 3 and 12 months after device activation, and thereafter annually. The 24‐h pad‐weight test (24hPWT) was used to assess severity of UI, while the Patient Global Impression of Improvement (PGI‐I) and patient satisfaction according to a Likert scale were used to measure patient‐reported outcomes.ResultsA total of 96 patients with a median (interquartile range [IQR]) age of 68 (65–72) years were included in the final analysis. The median (IQR) follow‐up was 3 (1–4) years. In all, 10 patients completed the 5‐year follow‐up. After the treatment, we observed a significant reduction in 24hPWT by the median of 83% (P < 0.001) at 3 months and by a median of 79% (P < 0.001) at 3 years. According to the PGI‐I, a total of 87%, 92%, 87%, 81%, 83%, and 50% (five of 10) of patients rated their condition/incontinence as ‘very much improved’, ‘much improved’ or ‘little improved’ at 3 months, 1‐, 2‐, 3‐, 4‐, and 5‐year follow‐up visits, respectively. The proportion of patients, who were ‘very satisfied’ or ‘satisfied’ with the treatment outcome was 79%, 80%, 75%, 69%, 80%, and 60% (six of 10) at 3 months, 1‐, 2‐, 3‐, 4‐, and 5‐years, respectively. There were a total of 13 (14%) device failures during the follow‐up period.ConclusionIn conclusion, our data suggest that Victo AUS significantly reduces the severity of UI after prostate surgery and provides a reasonably high patient‐reported satisfaction with treatment outcomes at mid‐term follow‐up.